Cortex and Samyang signed a memorandum of understanding granting Samyang South Korean rights to CX1739 for neurodegenerative diseases

Cortex Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$7.3m on 10/28/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Samyang Optics Co. Ltd.

South Korea / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Letter of Intent

Sample

01/01/2009

announced